Short answer
Candel Therapeutics, Inc. (CADL) filed an 8-K current report with the SEC on February 23, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 8.01 (Other Events). Offering priced at $5.45/share for 18,348,624 firm shares; underwriters hold 30-day option for 2,752,293 additional shares.
Candel Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Offering priced at $5.45/share for 18,348,624 firm shares; underwriters hold 30-day option for 2,752,293 additional shares
- Net proceeds ~$93.5M (or ~$107.6M if overallotment exercised fully): meaningful cash infusion for a clinical-stage biotech
- Proceeds earmarked for CAN-2409 prostate cancer commercial launch readiness and Phase 3 NSCLC trial costs
- Underwriters: Citigroup, Cantor Fitzgerald, and Stifel; institutional-grade syndicate signals credible market support
- Closing expected ~Feb 23, 2026; significant dilution event for existing shareholders given share count increase
Item 8.01 · Other Events
- Offering raises ~$93.5M net proceeds, extending cash runway into Q1 2028
- Underwriters hold option to purchase additional shares, potentially increasing total raise above $93.5M
- Runway extension is material: funds operational burn and capex for ~2 years from offering date
- Standard forward-looking caveat noted: actual burn rate could shorten the Q1 2028 timeline
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Candel Therapeutics, Inc. 8-K filings
Get the next CADL 8-K as it lands
Follow CADL for push alerts, or ask the research agent what this filing means.